Gene therapy researchers' assessments of risks and perceptions of risk acceptability in clinical trials

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 806-815

  Deakin, Claire T ^a,b   Alexander, Ian E ^a,c   Hooker, Cliff A ^b,d   Kerridge, Ian H ^b,e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE DRUG REACTION; ARTICLE; ATTITUDE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); FEMALE; GENE THERAPY; HUMAN; MALE; MORALITY; OUTCOME ASSESSMENT; PATIENT CARE; RESEARCHER ATTITUDE; RISK; RISK ACCEPTABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCIENTIST;

EID: 84878621656     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.230     Document Type: Article

References (41)

1. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodefciency (SCID)-X1 disease. Science 288: 669-672.
2. Hacein-Bey-Abina, S, Hauer, J, Lim, A, Picard, C, Wang, GP, Berry, CC et al. (2010). Effcacy of gene therapy for X-linked severe combined immunodefciency. N Engl J Med 363: 355-364.
3. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodefciency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
4. Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Adams, S, Howe, SJ et al. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodefciency. Sci Transl Med 3: 97ra79.
5. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
6. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodefciency due to adenosine deaminase defciency. N Engl J Med 360: 447-458.
7. Cavazzana-Calvo, M, Hacein-Bey, S, Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene Therapy of Human Severe Combined Immunodefciency (SCID)-X1 Disease. Science 288: 669-672.
8. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
9. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
10. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and effcacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
11. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Bougnères, P, Schmidt, M, Kalle, CV et al. (2012). Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Meth Enzymol 507: 187-198.
12. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467: 318-322.
13. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
14. Kang, EM, Choi, U, Theobald, N, Linton, G, Long Priel, DA, Kuhns, D et al. (2010). Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115: 783-791.
15. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modifed T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
16. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
17. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
18. Mitsuyasu, RT, Merigan, TC, Carr, A, Zack, JA, Winters, MA, Workman, C et al. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
19. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
20. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
21. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
22. Stocking, C, Bergholz, U, Friel, J, Klingler, K, Wagener, T, Starke, C et al. (1993). Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors 8: 197-209.
23. Hacein-Bey, H, Cavazzana-Calvo, M, Le Deist, F, Dautry-Varsat, A, Hivroz, C, Rivière, I et al. (1996). gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affnity interleukin-2 receptor expression and function. Blood 87: 3108-3116.
24. Hacein-Bey, S, Basile, GD, Lemerle, J, Fischer, A and Cavazzana-Calvo, M (1998). gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodefciency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 92: 4090-4097.
25. Hacein-Bey, S, Gross, F, Nusbaum, P, Hue, C, Hamel, Y, Fischer, A et al. (2001). Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. Hum Gene Ther 12: 291-301.
26. National Statistics Service. (2012). Sample size calculator 〈http://www.nss.gov.au/nss/home.nsf/pages/ Sample+Size+Calculator+Description?OpenDocument.
27. Catt, S, Langridge, C, Fallowfeld, L, Talbot, DC and Jenkins, V (2011). Reasons given by patients for participating, or not, in Phase 1 cancer trials. Eur J Cancer 47: 1490-1497.
28. Jenkins, V, Solis-Trapala, I, Langridge, C, Catt, S, Talbot, DC and Fallowfeld, LJ (2011). What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29: 61-68.
29. Miller, SM, Hudson, SV, Egleston, BL, Manne, S, Buzaglo, JS, Devarajan, K et al. (2012). The relationships among knowledge, self-effcacy, preparedness, decisional confict, and decisions to participate in a cancer clinical trial. Psychooncology (doi:10.1002/pon.3043).
30. Joffe, S, Cook, EF, Cleary, PD, Clark, JW and Weeks, JC (2001). Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 358: 1772-1777.
31. Joffe, S, Cook, EF, Cleary, PD, Clark, JW and Weeks, JC (2001). Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst 93: 139-147.
32. Truong, TH, Weeks, JC, Cook, EF and Joffe, S (2011). Outcomes of informed consent among parents of children in cancer clinical trials. Pediatr Blood Cancer 57: 998-1004.
33. Cook, C, Heath, F, and Thompson RL. (2000). A meta-analysis of response rates in web-or internet-based surveys. Educ Psychol Meas 60: 821-836.
34. Shih, TH, Fan, X. (2009). Comparing response rates from web and mail surveys: a meta-analysis. Educ Res Rev 4: 26-40.
35. Slovic, P (1987). Perception of risk. Science 236: 280-285.
36. Fischhoff, B, Lichtenstein, S, Slovic, P, Derby, SL and Keeney, RL. (1981). Acceptable Risk. Cambridge University Press: Cambridge MA.
37. Deakin, CT, Alexander, IE and Kerridge, I (2010). The ethics of gene therapy: balancing the risks. Curr Opin Mol Ther 12: 578-585.
38. R Development Core Team. (2012). R: A language and environment for statistical computing. 〈http://www.r-project.org/〉.
39. Zeger, SL, Liang, KY and Albert, PS (1988). Models for longitudinal data: a generalized estimating equation approach. Biometrics 44: 1049-1060.
40. (2008). Handbook of Longitudinal Research: Design, Measurement, and Analysis. Elsevier/Academic Press: Burlington, MA.
41. Rabe-Hesketh, S and Skrondal, A. (2008). Multilevel and Longitudinal Modeling Using Stata. Stata Press: College Station, TX.